Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-986528 in Refractory Rheumatoid Arthritis
NCT07412704Phase 2Recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Oct 2026
- Primary completion
- Oct 2029
- Modality
- Small Molecules
- Countries
- 11
01
Overview
A Phase 2 trial of BMS-986528 in Refractory rheumatoid arthritis (RRA), sponsored by Bristol Myers Squibb. Started Oct 2026; status: recruiting.
02
Drugs
BMS-986528
03
Conditions
Refractory rheumatoid arthritis (RRA)
Beyond the preview
Go deeper on NCT07412704.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07412704.